Business
Alligator Bioscience Presents New Data on Mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting
LUND, SE / ACCESS Newswire / November 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of two abstracts accepted ...
About this update from Alligator Bioscience Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / November 5, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced the publication of two abstracts accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held 5-9 November 2025 in National Harbor, MD, USA.","length":407,"tagName":"p"},{"type":"text","content":"The mitazalimab abstract presents new data from the OPTIMIZE-1 trial in metastatic pancreatic cancer, further characterizing efficacy, safety, and biomarker responses at two dose levels. These findings strengthen the clinical rationale for selecting the 900 μg/kg dose in the planned Phase 3 study and the exposure-response data further supports mitazalimab contribution to the clinical benefits observed in OPTIMIZE-1. Alligator will also present preclinical data on ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, demonstrating immune activation and remodeling of the tumor microenvironment.","length":606,"tagName":"p"},{"type":"text","content":"Mitazalimab presentation detailsTitle: CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 studyAbstract number: 530Time: Saturday, 8 November 2025Presenter: Yago Pico de Coaña, Medical Science Director, Alligator Bioscience","length":369,"tagName":"p"},{"type":"text","content":"Key findings:","length":13,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Improved survival outcomes at 6 months :","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"PFS: 50.8% vs. 38.7%","length":20,"tagName":"p"}]},{"val":[{"type":"text","content":"OS: 89.5% vs. 69.4%","length":19,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":39,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":79,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Manageable safety profile : Safety was manageable across both dose levels, with the increased rate of adverse events in the 900 μg/kg group attributed to extended treatment exposure","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Biomarker analyses : Greate...